CoolSculpting® And Kristin Davis Partner To Overcome Denim Denial Blues
-- Actress Named as Spokesperson for the World's #1 Nonsurgical Fat Reduction Treatment* --
DUBLIN, Oct. 23, 2018 /PRNewswire/ -- Actress for the Emmy- and Golden Globe-winning series "Sex and the City," philanthropist and mom, Kristin Davis, is partnering with CoolSculpting® – the FDA-cleared non-surgical, clinically proven treatment that eliminates stubborn fat using a patented cooling technology, owned by Allergan plc (NYSE: AGN) – as the partner of the "Denim Denial" consumer program. Denim Denial recognizes that every woman has a pair of jeans on the top shelf of her closet or tucked away in a bottom drawer but is holding on to them with the goal of fitting into them again someday when she frees herself of that last bit of stubborn fat. As the face of the program, Davis joins CoolSculpting® in its mission to inspire women across the country to learn more about personalized body contouring to achieve their own desired results, including fitting back into their favorite pair of denim.
"I'm excited to partner with CoolSculpting and help to banish Denim Denial. Jeans are a staple in every woman's wardrobe, and every woman wants to look great in them," said Davis. "I love that CoolSculpting is a non-surgical treatment that targets and eliminates fat and takes as little as 35 minutes with little to no downtime."
Davis will share her personal Denim Denial story on her social media channels and discuss her CoolSculpting® experience at an event in New York City on Wednesday, October 24, 2018, where she will join New York-based CoolSculpting provider Laura Dyer, MSHS, PA-C, to educate attendees on the proven science behind the more than 7 million CoolSculpting® treatments worldwide1.
"We are honored to partner with Kristin Davis for our Denim Denial program this fall and have her share her personal CoolSculpting® journey," said Brent Hauser, Vice President, Sales and Marketing, Body Contouring, Allergan. "With the help of Kristin Davis, CoolSculpting® is setting out to educate women about freezing away fat and solve the universal struggle that we all face at one point or another, Denim Denial."
Consumers can share their own Denim Denial stories on social media using #DenimDenial and #COOLnotcool.
References
* CoolSculpting is the treatment doctors use most for non-invasive fat removal.
1 Data on File Allergan, Inc.
About the CoolSculpting® Treatment
CoolSculpting® is a non-surgical, clinically proven treatment that selectively reduces unwanted fat using a patented cooling technology. Cleared by the FDA, CoolSculpting® works by gently cooling targeted fat cells in the body to induce a natural, controlled elimination of fat cells without affecting surrounding tissue, and the treated fat cells are gone for good. In 2018, CoolSculpting® was recognized for the fifth consecutive year by NewBeauty as a Choice Award winner. Millions of CoolSculpting treatments have been performed in more than 80 countries. CoolSculpting® is available through a network of CoolSculpting® Centers worldwide. Dermatologists, plastic surgeons and aesthetic specialists that offer CoolSculpting® can be found at www.coolsculpting.com.
In the U.S., the CoolSculpting® procedure is FDA-cleared for the treatment of visible fat bulges in the submental and submandibular areas, thigh, abdomen and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll) and upper arm. It is also FDA-cleared to affect the appearance of lax tissue with submental area treatments.
During the procedure you may experience sensations of pulling, tugging, mild pinching, intense cold, tingling, stinging, aching, and cramping at the treatment site. These sensations subside as the area becomes numb. Following the procedure, typical side effects include temporary redness, swelling, blanching, bruising, firmness, tingling, stinging, tenderness, cramping, aching, itching, or skin sensitivity, and sensation of fullness in the back of the throat after submental area treatment. Rare side effects may also occur. The CoolSculpting® procedure is not for everyone. You should not have the CoolSculpting® procedure if you suffer from cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria. The CoolSculpting® procedure is not a treatment for obesity. Please see full Important Safety Information for additional information.
Be sure to follow CoolSculpting® on Facebook, Twitter, Pinterest and YouTube.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.
Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
CONTACTS:
Allergan:
Investors:
Daphne Karydas
(862) 261-8006
Karina Calzadilla
(862) 261-7328
Media:
Marlo Rodman
(925) 918-1190
SOURCE Allergan plc
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article